Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fighting against intracellular pathogens: host cell-targeted drug delivery

  • Baranyai, Zsuzsa
Nanomedicine with active targeting strategies is one of the most promising approaches toensure that drug molecules reach their target sites and it brings us closer to eradicating harmful intracellular pathogens., This work has been supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 842652, by the Spanish MICINN project BIO2017-84246-C2-1-R and by Gobierno de Aragon (Diputacion General de Aragon-Fondo Social Europeo)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanotechnology-based targeted drug delivery: An emerging tool to overcome tuberculosis

  • Baranyai, Zsuzsa
  • Soria-Carrera, Héctor
  • Alleva, María
  • Millán-Placer, Ana C.
  • Lucía, Ainhoa
  • Martín-Rapún, Rafael
  • Aínsa, José A.
  • Fuente, Jesús M. de la
The appearance and rapid spread of drug resistant strains of tuberculosis (TB), one of the deadliest infectious diseases, pose a serious threat to public health and increase the need for shorter, less toxic, and more effective therapies. Developing new drugs is difficult and often associated with side effects, so nanotechnology has emerged as a tool to improve current treatments and to rescue drugs having elevated toxicity or poor solubility. Due to their size and surface chemistry, antimicrobial-loaded nanocarriers are avidly taken up by macrophages, the main cells hosting Mycobacterium tuberculosis. Macrophages are continuously recruited to infected areas, they can transport drugs with them, making passive targeting a good strategy for TB treatment. Active targeting (decorating surface of nanocarriers with ligands specific to receptors displayed by macrophages) further increases local drug concentration, and thus treatment efficacy. Although in in vivo studies, nanocarriers are often administered intravenously in order to avoid inaccurate dosage in animals, translation to humans requires more convenient routes like pulmonary or oral administration. This report highlights the importance and progress of pulmonary administration, passive and active targeting strategies toward bacteria reservoirs to overcome the challenges in TB treatment., This work was supported by the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Grant Agreement No. 842652, the Spanish MICINN projects (Grant Nos. BIO2017-84246-C2-1-R, SAF2017-84839-C2-1-R, and CTQ2015-66869-P), and by the Gobierno de Aragón (Diputación General de Aragón–Fondo Social Europeo). R.M.-R. acknowledges MICINN for funding through the Ramón y Cajal Program (Grant No. RYC-2013-12570). H.S.-C. and A.C.M.-P. are grateful for FPU predoctoral contracts from Ministerio de Educación Cultura y Deporte (Spain) and M.A. is grateful for a predoctoral contract from Gobierno de Aragón (Diputación General de Aragón–Fondo Social Europeo)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

A personal experience with the Marie Skłodowska Curie Actions Individual Fellowship

  • Baranyai, Zsuzsa
Trabajo presentado al MSCA Individual Fellowships Webinar, celebrado en Zaragoza (España) el 15 de mayo de 2020., TBNANO (Grant agreement ID: 842652., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Antitubercular drug delivery with functionalized nanocapsules

  • Baranyai, Zsuzsa
  • Alleva, María
  • Martínez-Vicente, Pablo
  • Moros, María
  • Millán-Placer, Ana C.
  • Aínsa, José A.
  • Fuente, Jesús M. de la
Resumen del trabajo presentado a la 4th SBAN Spanish Conference on Biomedical Applications of Nanomaterials (SBAN), celebrada online del 2 al 4 de junio de 2021., This work was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 842652., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Synthesis and characterization of antitubercular drug-loaded functionalized nanocapsules

  • Baranyai, Zsuzsa
  • Alleva, María
  • Martínez-Vicente, Pablo
  • Fuente, Jesús M. de la
Resumen del póster presentado al Chemical Nanosciences and Nanotech Early Career Virtual Poster Symposium, celebrado online el 24 de marzo de 2021., This work was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 842652., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Antitubercular drug delivery with polysaccharide-based nanocarriers

  • Baranyai, Zsuzsa
  • Alleva, María
  • Martínez-Vicente, Pablo
  • Moros, María
  • Millán-Placer, Ana C.
  • Picó, Ana
  • Aínsa, José A.
  • Fuente, Jesús M. de la
Resumen del póster presentado a la 13th International Symposium on Polymer Therapeutics: from Laboratory to Clinical Practice, celebrada en Valencia (España) del 23 al 24 de mayo de 2022., This work was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 842652 and the CSIC’s MSCA IF extension., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Development of functionalized nanocarriers for drug targeting in tuberculosis

  • Baranyai, Zsuzsa
  • Alleva, María
  • Martínez-Vicente, Pablo
  • Moros, María
  • Millán-Placer, Ana C.
  • Picó, Ana
  • Aínsa, José A.
  • Fuente, Jesús M. de la
Resumen del trabajo presentado al Annual Meeting of the Controlled Release Society, celebrado en Montreal (Canada) el 11 de julio de 2022., This work was supported by the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 842652 and the CSIC’s MSCA IF extension., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Förster Resonance Energy Transfer (FRET) demonstrates in vitro chitosan-coated nanocapsules suitability for intranasal brain delivery

  • Alleva, María
  • Baranyai, Zsuzsa
  • Esteban-Pérez, Natalia
  • Martínez-Vicente, Pablo
  • Martín-Rapún, Rafael
  • Moros, María
  • Fuente, Jesús M. de la
Intranasal drug delivery to the brain offers a promising strategy to overcome biological barriers. Chitosan-coated nanoemulsion-based nanocapsules demonstrate significant potential due to their mucoadhesive properties, ability to permeate epithelial cells, and ability to solubilize poorly water-soluble drugs, making them ideal candidates for bypassing the blood-brain barrier and overcoming the nasal mucosa. To ensure effective drug delivery, it is critical to assess the integrity of these nanocapsules during their transit across such barriers. In this study, we employed Förster resonance energy transfer to track the structural integrity of nanocapsules during transport. A simplified in vitro model was established using Calu-3 cells to mimic the mucosal epithelial barrier and Balb-c 3T3 fibroblasts as target cells. Our findings demonstrated that the nanoemulsion core of the nanocapsules successfully crossed the in vitro epithelial barrier and reached target cells while maintaining its structural integrity. These results validate the potential of chitosan-coated nanocapsules as a robust platform for the intranasal delivery of drugs to the brain., This work has been supported by MICIU/AEI/10.13039/501100011033 (PID2020-118485RB-I00, and ayuda Severo Ochoa CEX2023-001286-S), by CIBER-Consorcio Centro de Investigación Biomédica en Red/Instituto de Salud Carlos III (CB16/01/00263). This research work was also funded by the European Commission–NextGenerationEU (Regulation EU 2020/2094) through CSIC’s Global Health Platform (PTI Salud Global), and by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 842652 and the CSIC’s MSCA IF extension. MA and NEP acknowledge Gobierno de Aragón for predoctoral fellowships (2019–2023 and 2022–2026). The authors also acknowledge support from Gobierno de Aragón and “ERDF A way of making Europe” for funding the Bionanosurf (E15_20R) research group., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2023-001286-S)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Nanotechnology-Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

  • Baranyai, Z.
  • Soria-Carrera, H.
  • Alleva, M.
  • Millan-Placer, A.C.
  • Lucia, A.
  • Martin-Rapun, R.
  • Ainsa, J.A.
  • de la Fuente, J.M.
The appearance and rapid spread of drug resistant strains of tuberculosis (TB), one of the deadliest infectious diseases, pose a serious threat to public health and increase the need for shorter, less toxic, and more effective therapies. Developing new drugs is difficult and often associated with side effects, so nanotechnology has emerged as a tool to improve current treatments and to rescue drugs having elevated toxicity or poor solubility. Due to their size and surface chemistry, antimicrobial-loaded nanocarriers are avidly taken up by macrophages, the main cells hostingMycobacterium tuberculosis. Macrophages are continuously recruited to infected areas, they can transport drugs with them, making passive targeting a good strategy for TB treatment. Active targeting (decorating surface of nanocarriers with ligands specific to receptors displayed by macrophages) further increases local drug concentration, and thus treatment efficacy. Although in in vivo studies, nanocarriers are often administered intravenously in order to avoid inaccurate dosage in animals, translation to humans requires more convenient routes like pulmonary or oral administration. This report highlights the importance and progress of pulmonary administration, passive and active targeting strategies toward bacteria reservoirs to overcome the challenges in TB treatment. La aparición y la rápida propagación de cepas de tuberculosis (TB) resistentes a los medicamentos, una de las enfermedades infecciosas más mortales, representan una grave amenaza para la salud pública y aumentan la necesidad de tratamientos más breves, menos tóxicos y más eficaces. El desarrollo de nuevos fármacos es difícil y, a menudo, se asocia con efectos secundarios, por lo que la nanotecnología se ha convertido en una herramienta para mejorar los tratamientos actuales y rescatar fármacos que tienen una toxicidad elevada o una solubilidad deficiente. Debido a su tamaño y química de superficie, los nanoportadores cargados de antimicrobianos son absorbidos con avidez por los macrófagos, las principales células que albergan Mycobacterium tuberculosis.. Los macrófagos se reclutan continuamente en las áreas infectadas, pueden transportar medicamentos con ellos, lo que hace que la focalización pasiva sea una buena estrategia para el tratamiento de la TB. La focalización activa (decoración de la superficie de los nanoportadores con ligandos específicos de los receptores mostrados por los macrófagos) aumenta aún más la concentración local del fármaco y, por lo tanto, la eficacia del tratamiento. Aunque en estudios in vivo, los nanotransportadores a menudo se administran por vía intravenosa para evitar dosis inexactas en animales, la traducción a humanos requiere vías más convenientes, como la administración pulmonar u oral. Este informe destaca la importancia y el progreso de la administración pulmonar, las estrategias de orientación pasiva y activa hacia los reservorios de bacterias para superar los desafíos en el tratamiento de la TB.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Förster resonance energy Transfer (FRET) demonstrates in vitro chitosan-coated nanocapsules suitability for intranasal brain delivery

  • Alleva, María
  • Baranyai, Zsuzsa
  • Esteban-Pérez, Natalia
  • Martínez-Vicente, Pablo
  • Martín-Rapún, Rafael
  • Moros, María
  • Martínez de la Fuente, Jesús
Intranasal drug delivery to the brain offers a promising strategy to overcome biological barriers. Chitosan-coated nanoemulsion-based nanocapsules demonstrate significant potential due to their mucoadhesive properties, ability to permeate epithelial cells, and ability to solubilize poorly water-soluble drugs, making them ideal candidates for bypassing the blood-brain barrier and overcoming the nasal mucosa. To ensure effective drug delivery, it is critical to assess the integrity of these nanocapsules during their transit across such barriers. In this study, we employed Förster resonance energy transfer to track the structural integrity of nanocapsules during transport. A simplified in vitro model was established using Calu-3 cells to mimic the mucosal epithelial barrier and Balb-c 3T3 fibroblasts as target cells. Our findings demonstrated that the nanoemulsion core of the nanocapsules successfully crossed the in vitro epithelial barrier and reached target cells while maintaining its structural integrity. These results validate the potential of chitosan-coated nanocapsules as a robust platform for the intranasal delivery of drugs to the brain.